Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Code of Conduct

Listed below are links to the various Codes of Conduct that Trovagene operates under.

Code of Business Conduct and Ethics

Trovagene's Board of Directors approved Revision 02 of the Business Code of Conduct and Ethics effective as of December 05, 2018.